grant
microRNA, immunophenotypic, and somatic alterations in hematologic malignancies
Organization CLINICAL CENTERLocation UNITED STATES
NIHUS FederalResearch GrantFY20255q Deletion5q-AML/MDSAML1AMLCR1APAF-3APAF3Aberrant ChromosomeActive Follow-upAlgorithmsAntioncogene Protein p53Apaf-3 proteinAplastic AnemiaApoptosisApoptosis PathwayApoptosis-Related Cysteine Protease Caspase 9Apoptosis-Related Cysteine Protease Gene Caspase 9Apoptotic Protease Activating Factor 3Apoptotic Protease Activating Factor 3 GeneApoptotic Protease MCH-6Apoptotic Protease MCH-6 GeneAutoimmuneBCL2L11BCL2L11 geneBIMBIMELBIMLBimMELBindingBioconductorBiologyBlood DiseasesBlood Platelet CountBlood Platelet NumberBlood leukocyteBone MarrowBone Marrow Blood-Deriving CellBone Marrow Blood-Forming CellBone Marrow CellsBone Marrow DiseasesBone Marrow Reticuloendothelial SystemBone marrow failureCASP-9CASP9CASP9 ProteinCASP9 geneCBFA2CD152CD152 AntigenCD152 GeneCTLA 4CTLA-4 GeneCTLA4CTLA4 geneCTLA4-TMCaspase-9 GeneCell BodyCell FunctionCell LineCell PhysiologyCell ProcessCellLineCellsCellular FunctionCellular PhysiologyCellular ProcessCellular Tumor Antigen P53Chemotactic CytokinesChromosomal AberrationsChromosomal AbnormalitiesChromosomal AlterationsChromosome AberrationsChromosome AlterationsChromosome AnomaliesChromosome abnormalityClassificationClinicalCollaborationsConsensusControl GroupsCytogenetic AberrationsCytogenetic AbnormalitiesCytogeneticsCytotoxic T-Lymphocyte Protein 4Cytotoxic T-Lymphocyte-Associated Antigen 4Cytotoxic T-Lymphocyte-Associated Protein 4Cytotoxic T-Lymphocyte-Associated Serine Esterase-4DNA AlterationDNA Damage RepairDNA MethylationDNA RepairDNA Sequence AlterationDNA mutationDNMT3aData AnalysesData AnalysisData CorrelationsDevelopmentDiagnosisDifferential Gene ExpressionDiseaseDisease ProgressionDisorderDysmyelopoietic SyndromesDysplasiaENX-1ETS Variant Gene 6ETV6ETV6 geneEZH1EZH2EZH2 geneEmberger syndromeEnhancer of Zeste 2 Polycomb Repressive Complex 2 SubunitEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEvaluationExpression SignatureFLK2FLT3FLT3 geneFMS-like tyrosine kinase 3Fms-Related Tyrosine Kinase 3GATA2 deficiencyGATA2 haploinsufficiencyGene Expression ProfileGenesGeneticGenetic AlterationGenetic ChangeGenetic defectGenetic mutationGenome MappingsGenomic DNAGenotypeGerm LinesGerm-Line MutationGoalsHHR23BHematologic CancerHematologic DiseasesHematologic MalignanciesHematologic NeoplasmsHematological DiseaseHematological DisorderHematological MalignanciesHematological NeoplasmsHematological TumorHematopoiesisHematopoietic CancerHematopoietic Cellular Control MechanismsHemoglobin concentration resultHereditaryHereditary MutationHomologous Chemotactic CytokinesICE-LAP6ICE-LAP6 GeneICE-LAP6 proteinICE-Like Apoptotic Protease 6ICE-Like Apoptotic Protease 6 GeneImmunohistochemistryImmunohistochemistry Cell/TissueImmunohistochemistry Staining MethodImmunologic SubtypingImmunophenotypingInheritedIntercrinesInternationalInvestigationKMT6KMT6ALaboratoriesLeukocytesLeukocytes Reticuloendothelial SystemLymphatic cellLymphocyteLymphocyticMCH6Malignant Hematologic NeoplasmMarrowMarrow leukocyteMch6 proteinMessenger RNAMethylationMicroRNAsMolecularMolecular InteractionMonoMACMononuclearMorphologyMutationMutation AnalysisMyelodysplastic DiseaseMyelodysplastic SyndromesMyelogenousMyeloidMyeloid DiseaseMyeloid MalignancyMyeloid NeoplasmMyeloid TumorMyeloproliferative DisordersMyeloproliferative TumorsMyeloproliferative diseaseNGS MethodNGS systemNetwork AnalysisOncogenesisOncoprotein p53OntologyOpticsOutcomeP53PEBP2A2PEBP2aBPathologyPathway AnalysisPathway interactionsPatientsPhenotypePhosphoprotein P53Phosphoprotein pp53Platelet CountPlatelet Count measurementPlatelet NumberPost-Transcriptional ControlPost-Transcriptional RegulationPredispositionProductionProgrammed Cell DeathProliferatingProtein TP53RAD23BRAD23B geneRNA SeqRNA sequencingRNAseqRUNX1RUNX1 geneRefractory Anemia with an Excess of BlastsRefractory anaemia with excess blastsRegulationRoleSIS cytokinesSTK-1 kinaseSTK1Sequence AlterationSeverity of illnessSmoldering LeukemiaSomatic MutationStaining methodStainsStem Cell Tyrosine Kinase 1Strains Cell LinesSubcellular ProcessSusceptibilitySyndromeSystematicsT cell differentiationTEL GeneTP53TP53 geneTRP53TimeTissue-Specific Differential Gene ExpressionTissue-Specific Gene ExpressionTranscriptTranslational InhibitionTranslational RepressionTumor Protein p53Tumor Protein p53 GeneUnscheduled DNA SynthesisWhite Blood CellsWhite CellWorkWorld Health Organizationactive followupacute myeloid leukemia/myelodysplastic syndromeblood cell formationblood disorderbone marrow disordercandidate selectioncaspase-9chemoattractant cytokinechemokinechromosomal defectchromosome 13q losschromosome 20q losschromosome 5q losschromosome defectcultured cell linecytokinecytopeniacytotoxic T-lymphocyte antigen 4data interpretationdel(13q)del(20q)del(5q)developmentaldiagnostic criteriadisease severitydyscrasiaepigeneticallyexperimentexperimental researchexperimental studyexperimentsfetal liver kinase-2fetal liver kinase-3follow upfollow-upfollowed upfollowupgDNAgene expression patterngene expression signaturegenome mutationgenomic alterationgerm-line defectgermline varianthDNA methyltransferase 3ahemoglobin levelinsightlymph cellmRNAmiRNAmigrationmyelodysplasiamyeloproliferative neoplasmnext gen sequencingnext generation sequencingnextgen sequencingnovelopticalp53 Antigenp53 Genesp53 Tumor Suppressorpathwayperipheral bloodpost-transcriptional gene regulationprotein p53research studyresponse to therapyresponse to treatmentsocial rolesomatic varianttherapeutic responsetherapy responsetranscriptional profiletranscriptional signaturetranscriptome sequencingtranscriptomic sequencingtranscriptomicstreatment responsetreatment responsivenesstumorigenesiswhite blood cellwhite blood corpuscle
Description preview
1. Methylation study on bone marrow of GATA2 deficiency vs. healthy control marrow. In order to identify the potential role of epigenetics in the bone marrow pathology of GATA2 deficiency and the development of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) we performed methylation studies. DNA methylation microarray (Illumina EPICv2)…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click